Abivax SA Sponsored ADR (ABVX) Price & Analysis

Compare

184 Followers

ABVX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.77 - $72.90

Previous CloseN/A

Volume62.24K

Average Volume (3M)1.96M

Market Cap

$4.96B

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta2.60

Next Earnings

Sep 08, 2025

EPS Estimate

-0.93

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.97

Shares Outstanding63,471,930

10 Day Avg. Volume5,192,494

30 Day Avg. Volume1,957,775

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$85.29

Price Target Upside28.12% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsObefazimod exceeded investor and company expectations on the FDA primary endpoint of clinical remission, achieving significant benefits across all primary and key secondary endpoints.

Market PotentialObefazimod now has the most compelling late-stage clinical profile for a novel oral agent in ulcerative colitis with potential to address a clear unmet need in the massive ~$30bn market for IBD therapeutics.

Regulatory ProspectsBoth doses of obefazimod met European Medicines Agency co-primary endpoints, strengthening confidence in the potential for regulatory approval.

Bears Say

Dose EfficacyThe lower 25mg QD dose was not statistically significant on clinical remission in ABTECT-2, although other relevant endpoints were significant.

Abivax SA Sponsored ADR News

Abivax price target raised to $112 from $70 at Piper Sandler

Piper Sandler raised the firm’s price target on Abivax (ABVX) to $112 from $70 and keeps an Overweight...

1d ago

ABVX

Abivax prices 10.2M ADSs at $64.00 in underwritten public offering

Abivax (ABVX) announces the pricing of its previously announced underwritten public offering of 10,156,000 American Depositary Shares, each...

6d ago

ABVX

Abivax 10.16M ADS offering priced at $64.00

Abivax (ABVX) announces the pricing of its previously announced underwritten public offering of 10,156,000 American Depositary Shares, each...

6d ago

ABVX

Abivax announces trading resumption of shares on Euronext Paris

Abivax (ABVX) announced the trading resumption of its ordinary shares on the regulated market of Euronext Paris as...

6d ago

ABVX

Why Is Abivax Stock (ABVX) Up 490% Today?

Abivax stock rocketed higher on Wednesday after it posted positive Phase 3 clinical trial data. ...

7d ago

ABVX

Abivax $400M Spot Secondary; price range $62.50-$65.00

Leerink, Piper Sandler, Guggenheim and LifeSci Capital are acting as joint book running managers for the offering. Published...

7d ago

ABVX

Abivax announces $400M ADS offering

Abivax (ABVX) SA announced the launch of an approximately $400M underwritten public offering consisting of a public offering...

7d ago

ABVX

Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!

Investors are halfway through the week and there’s plenty of stock market news worth checking out. ...

7d ago

DIA

Trump announces tariff deal with Japan, AT&T reports Q2 beat: Morning Buzz

The major averages were broadly higher near noon following several mixed days. The surprise announcement of a U.S.-Japan...

7d ago

Abivax price target raised to $101 from $45 at LifeSci Capital

LifeSci Capital raised the firm’s price target on Abivax (ABVX) to $101 from $45 and keeps an Outperform...

7d ago

ABVX

Abivax upgraded to Overweight from Equal Weight at Morgan Stanley

Morgan Stanley upgraded Abivax (ABVX) to Overweight from Equal Weight with a price target of $71, up from...

7d ago

ABVX

Abivax upgraded to Overweight at Morgan Stanley after obefazimod data

Morgan Stanley analyst Judah Frommer upgraded Abivax (ABVX) to Overweight from Equal Weight with a price target of...

7d ago

ABVX

Abivax SA Announces $608.6 Million Public Offering of ADSs

Abivax SA Sponsored ADR ( ($ABVX) ) has provided an announcement. On July 23, 2025, Abivax SA entered...

6d ago

ABVX

Abivax SA’s Obefazimod: Strong Phase 3 Results and Promising Market Potential Justify Buy Rating

Abivax SA Sponsored ADR, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Thomas...

6d ago

ABVX

ABVX FAQ

What was Abivax SA Sponsored ADR’s price range in the past 12 months?

Abivax SA Sponsored ADR lowest stock price was $4.77 and its highest was $72.90 in the past 12 months.

What is Abivax SA Sponsored ADR’s market cap?

Abivax SA Sponsored ADR’s market cap is $4.96B.

When is Abivax SA Sponsored ADR’s upcoming earnings report date?

Abivax SA Sponsored ADR’s upcoming earnings report date is Sep 08, 2025 which is in 40 days.

How were Abivax SA Sponsored ADR’s earnings last quarter?

Abivax SA Sponsored ADR released its earnings results on Jun 02, 2025. The company reported -$0.969 earnings per share for the quarter, missing the consensus estimate of -$0.756 by -$0.213.

Is Abivax SA Sponsored ADR overvalued?

According to Wall Street analysts Abivax SA Sponsored ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Abivax SA Sponsored ADR pay dividends?

Abivax SA Sponsored ADR does not currently pay dividends.

What is Abivax SA Sponsored ADR’s EPS estimate?

Abivax SA Sponsored ADR’s EPS estimate is -0.93.

How many shares outstanding does Abivax SA Sponsored ADR have?

Abivax SA Sponsored ADR has 63,471,930 shares outstanding.

What happened to Abivax SA Sponsored ADR’s price movement after its last earnings report?

Abivax SA Sponsored ADR reported an EPS of -$0.969 in its last earnings report, missing expectations of -$0.756. Following the earnings report the stock price went up 21.89%.

Which hedge fund is a major shareholder of Abivax SA Sponsored ADR?

Currently, no hedge funds are holding shares in ABVX

Abivax SA Sponsored ADR Stock Smart Score

Outperform

Fundamentals

Return on Equity

-147.48%

Trailing 12-Months

Asset Growth

-41.18%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Abivax SA Sponsored ADR

Abivax SA Sponsored ADR (ABVX) is a biotechnology company focused on developing therapies for inflammatory diseases, viral infections, and cancer. The company's core products are centered around its proprietary drug candidates, which are designed to modulate the immune response in patients. Abivax operates primarily in the biopharmaceutical sector, leveraging its research and development capabilities to bring innovative solutions to market.

Abivax SA Sponsored ADR (ABVX) Earnings & Revenues

ABVX Earnings Data >

ABVX Stock 12 Month Forecast

Average Price Target

$85.29

▲(28.12%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","113":"$113","31.25":"$31.3","58.5":"$58.5","85.75":"$85.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":112,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$112.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":85.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$85.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$43.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,31.25,58.5,85.75,113],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.66,15.686153846153847,23.712307692307693,31.73846153846154,39.76461538461538,47.79076923076923,55.816923076923075,63.84307692307692,71.86923076923077,79.89538461538461,87.92153846153846,95.94769230769231,103.97384615384615,{"y":112,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.66,13.631538461538462,19.603076923076927,25.574615384615388,31.54615384615385,37.517692307692315,43.48923076923077,49.46076923076923,55.4323076923077,61.40384615384616,67.37538461538462,73.34692307692308,79.31846153846155,{"y":85.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.66,10.37846153846154,13.096923076923078,15.815384615384616,18.533846153846156,21.252307692307696,23.970769230769232,26.68923076923077,29.40769230769231,32.126153846153855,34.844615384615395,37.56307692307693,40.28153846153846,{"y":43,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.97,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.04,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.56,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.71,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.97,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.48,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.32,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.68,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.89,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.91,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.35,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.66,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >